CARGI 10mg

Description

CARGI 10mg

Cagrilintide acts as an innovative long-acting amylin analog that activates both amylin and calcitonin receptors. Its uniqueness lies in its ability to trigger a satiety signal in the brain, affecting areas of the brain responsible for both homeostasis and enjoyment of food. Through this mechanism, cagrilintide has the potential to reduce food intake and promote weight loss for patients. In addition, its long-lasting effect allows application once a week, which is convenient for patients【5†source】.

CARGI 10mg: Cagrilintide, in combination with semaglutide, is currently being developed for the treatment of type 2 diabetes, obesity and metabolically associated steatohepatitis (MASH). This therapy is administered via the subcutaneous route and combines cagrilintide, which acts by targeting calcitonin receptor and receptor activity modifying proteins 1, 2, 3 (RAMP 1-3), and semaglutide, which acts on glucagon-like receptor 1(GLP1R)【6†source】.

Currently, the combination of cagrilintide and semaglutide is in Phase III clinical trials for the treatment of type 2 diabetes. These processes are key to the drug’s final approval and launch as a new therapeutic option for patients【6†source】.

The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.